Company: RGNX
Filing Date: 2025-03-04
Form Type: 8-K
Source: 0001193125-25-045585
Chunk: 1

Company: REGENXBIO Inc.
Filing Date: 2025-03-04
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01 Regulation FD Disclosure.

On March 4, 2025, the Company issued a press release announcing the closing of the Collaboration and License Agreement. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form8-Kand Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

  Item 9.01.      Financial Statements and Exhibits.  

(d) Exhibits

  Exhibit      Description                                                                   
      No.                                                                                    
     99.1      Press release dated March 4, 2025.                                            
 ─────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (embedded within the Inline XBRL document).  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                    REGENXBIO INC.                                 
  Date: March 4, 2025      By:      /s/ Patrick J. Christmas II                    
                                    Patrick J. Christmas II